Oil-Free Mold Technology: A Breakthrough in Hollow Capsule Production

Dec 31, 2025

Leave a message

October 2025 marks a pivotal advancement in the pharmaceutical packaging industry with the successful development and commercialization of oil-free dip molding technology for hollow capsule production. At the core of this innovation lies a groundbreaking chromium-chromium nitride composite coating technology, which has effectively addressed long-standing pain points in traditional capsule manufacturing processes, particularly the pollution risks and high costs associated with oil-based release agents.

 

The newly developed composite coating is engineered with precise specifications to optimize mold performance: a thickness ranging from 3 to 5 micrometers, a surface roughness of 0.06-0.09 Ra, and an ultra-high Vickers hardness of 1500-2000 HV. This combination of parameters is not arbitrary but the result of rigorous material science research. The chromium-chromium nitride coating is deposited using advanced physical vapor deposition (PVD) technology, specifically multi-arc ion plating, which ensures a dense, uniform film with strong adhesion to the mold substrate-exceeding 70 N/mm² in bonding strength. This structural integrity prevents coating peeling even under the repeated mechanical stress of high-speed capsule production cycles.

 

The ultra-low surface roughness (0.06-0.09 Ra) is a key enabler of the oil-free functionality. According to mold surface engineering standards, this Ra range falls into the high-precision surface category, significantly reducing the friction coefficient between the mold surface and the capsule material (such as gelatin or HPMC). Compared to traditional molds with typical Ra values of 0.8-1.6 μm, the smooth surface of the coated mold eliminates the need for oil-based release agents to facilitate demolding. This not only streamlines the production process but also eliminates the risk of oil residue contamination on capsules-a critical quality concern in pharmaceutical manufacturing that could compromise drug safety and efficacy.

 

The ultra-high hardness of 1500-2000 HV further enhances the technology's practical value. This hardness level is 8-10 times higher than that of conventional electroplated hard chrome molds, drastically improving wear resistance and extending mold lifespan. In field tests, the coated molds maintained their performance through over 500,000 production cycles, a significant leap from the 50,000-100,000 cycles of traditional oil-lubricated molds. For capsule manufacturers, this translates to reduced mold replacement costs and less production downtime.

 

Beyond quality and durability improvements, the oil-free technology delivers substantial environmental and economic benefits by addressing the flaws of traditional oil-based processes. Traditional mold oiling operations generate volatile organic compounds (VOCs)-a major contributor to PM2.5 and air pollution-and produce wastewater containing heavy metals and non-biodegradable oils, which require expensive treatment to meet environmental standards. A lifecycle analysis conducted by a leading pharmaceutical equipment supplier shows that adopting the oil-free mold technology reduces VOC emissions by over 70% and cuts wastewater treatment costs by 60% compared to conventional processes. Additionally, the elimination of release agent procurement eliminates a recurring operational expense, reducing overall production costs by 15-20% for medium to large-scale capsule manufacturers.

 

Industry experts anticipate that this oil-free mold technology will accelerate the transformation of the hollow capsule production sector towards greener and more intelligent manufacturing. As pharmaceutical regulatory standards for packaging safety and environmental protection become increasingly stringent globally, the chromium-chromium nitride composite coated molds are poised to replace traditional oil-lubricated molds as the new industry standard. Initial adoptions by major capsule producers in China, Europe, and Southeast Asia have already demonstrated stable production performance, with capsule defect rates reduced to below 0.3%-a new benchmark for the industry.